Related Experiment Videos
The management of retinopathy of prematurity
1State University of New York at Buffalo, Children's Hospital, 14222, USA.
Insights
Retinopathy of prematurity (ROP) remains a significant cause of blindness in premature infants despite advances in neonatology. New preventative treatments are crucial for improving visual outcomes in these vulnerable newborns.
Area of Science:
- Ophthalmology
- Neonatology
- Perinatal Medicine
Background:
- Retinopathy of prematurity (ROP) is a leading cause of blindness in premature infants, affecting approximately 5% of those with low birth weights.
- Despite improvements in neonatal care, the incidence of ROP has remained stable, with a significant minority experiencing vision loss even after treatment.
- The pathophysiology involves two phases: hyperoxia-induced vascular cessation followed by hypoxia-driven neovascularization, mediated by vascular endothelial growth factor (VEGF).
Purpose of the Study:
- To review the current understanding of retinopathy of prematurity (ROP) pathophysiology and management.
- To highlight the challenges in preventing and treating ROP and identify areas for future research.
- To emphasize the need for improved screening protocols and collaborative efforts among healthcare professionals.
Main Methods:
- Review of existing literature on ROP pathophysiology, screening, and treatment modalities.
- Analysis of the two-phase disease process: Phase I (hyperoxia-vasocessation) and Phase II (hypoxia-vasoproliferation).
- Evaluation of current management strategies including prevention, interdiction (retinal ablation), and correction (vitrectomy).
Main Results:
- Current treatments like cryotherapy and laser photocoagulation for ROP are effective but associated with persistent poor visual outcomes.
- Preventive measures such as adequate prenatal care and optimized neonatal intensive care are essential.
- Investigational therapies like inositol and angiogenesis inhibitors show potential for ROP prevention, while supplemental oxygen has not proven effective in limiting progression.
Conclusions:
- Retinopathy of prematurity (ROP) continues to pose a significant threat to vision in premature infants globally.
- Effective management requires a multi-faceted approach encompassing robust screening, prevention, and novel therapeutic strategies.
- Future research should focus on developing innovative treatments, particularly those aimed at preventing ROP development and progression.
Abstract:
Retinopathy of prematurity (ROP) is a major problem in both highly developed countries and countries with emerging technology. The incidence of ROP has been stable over the last 2 decades despite improvements in neonatology. Threshold ROP occurs in about 5% of premature infants in the US with birthweights <1.25kg. Despite treatment, a sizable minority will become blind (up to 20 to 30%). The pathophysiology of ROP can be separated into 2 phases. Phase I is hyperoxia-vasocessation. Phase II is hypoxia-vasoproliferation. The former occurs immediately following premature birth. The provision of supplemental oxygen causes retinal hyperoxia, a down regulation of vascular endothelial growth factor (VEGF) and a consequent cessation of normal retinal vascularisation. Systemic factors and increasing retinal metabolic demands cause a shift to phase II when a relative retinal hypoxia develops. This hypoxia stimulates VEGF production, leading to renewed vascularisation. This can be the resumption of normal vascularisation or abnormal neovascularisation, depending on local retinal responses. The management of ROP begins with a reliable evidence-based screening protocol. All interested parties must cooperate in developing and implementing foolproof screening protocols. Hospital officials, nursery personnel, neonatologists and ophthalmologists all have areas of responsibility in ensuring adequate screening. ROP management involves prevention, interdiction and correction. Prevention includes: adequate prenatal care which minimises premature birth, and appropriate systemic intensive care which lessens the tissue hyperoxia/hypoxia swings. Pharmacological vitamin E supplementation has largely been abandoned and ambient light reduction has been shown to be ineffective. The value of inositol supplementation and angiogenesis inhibitors in preventing ROP is presently under investigation. Interdiction concentrates on ablation of the peripheral avascular retina, thus dramatically decreasing VEGF production. Both cryotherapy and laser photocoagulation are effective; however, unfortunately, poor outcomes persist despite treatment. Supplemental oxygen administration has so far proven ineffective in limiting ROP progression. Finally, correction focuses on vitrectomy/retinal detachment repair. While anatomically successful, this procedure is often unsuccessful in terms of restoration of vision (<5% success rate). In conclusion, despite improvements in neonatology, ROP, potentially leading to blindness, continues to be a common problem associated with prematurity. Future management success must concentrate on discovering new modes of treatment, especially prevention.